Evaluating the use of early hormonal therapy in patients with localised or locally advanced prostate cancer

被引:10
|
作者
Kaisary, AV [1 ]
机构
[1] Royal Free Hosp, Dept Urol, London NW3 2QG, England
关键词
prostate cancer; hormonal therapy; castration; luteinising hormone-releasing hormone agonist; nonsteroidal antiandrogen;
D O I
10.1038/sj.pcan.4500800
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
This article evaluates the use of early hormonal therapy in patients with localised or locally advanced prostate cancer. In patients receiving radiotherapy, an overall survival benefit is proven for adjuvant goserelin ('Zoladex') in locally advanced disease. Adjuvant to radical prostatectomy, castration ( goserelin or orchiectomy) has demonstrated an overall survival benefit in patients with lymph node metastases. Survival advantages have not yet been proven with nonsteroidal antiandrogens, but immediate or adjuvant bicalutamide ('Casodex') improves objective progression-free survival in patients with locally advanced disease, with certain quality-of-life advantages over castration.
引用
收藏
页码:140 / 151
页数:12
相关论文
共 50 条